Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction

NCT02567396 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02567396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02567396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2016
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, head and neck squamous cell carcinoma, her2/neu negative, hormone-resistant prostate cancer, metastatic pancreatic adenocarcinoma, progesterone receptor negative, solid neoplasm, stage iii mesothelioma, stage iiia gastric cancer, stage iiia non-small cell lung cancer, stage iiia ovarian cancer, stage iiia small cell lung carcinoma, stage iiib gastric cancer, stage iiib non-small cell lung cancer, stage iiib ovarian cancer, stage iiib small cell lung carcinoma, stage iiic gastric cancer, stage iiic ovarian cancer, stage iv mesothelioma, stage iv non-small cell lung cancer, stage iv ovarian cancer, stage iv small cell lung carcinoma, triple-negative breast carcinoma